GlassScriptPhysician profile
Fanar Alyas
NPI 1932468097
$7,308.86
in general payments reported to CMS, 2019-2025
50 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $18.09 · 2021: $333 · 2022: $901 · 2023: $2,143 · 2024: $2,396 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,932.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $840.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $713.36 | 2022-2025 | Linzess, Vraylar, Creon |
| Lilly USA, LLC | $688.65 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $546.92 | 2021-2025 | Breztri, Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $452.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $426.80 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $424.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $340.72 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $286.77 | 2022-2025 | Eliquis |
| Amgen INC. | $265.34 | 2021-2024 | Otezla, Repatha, Enbrel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.75 | 2021-2024 | Ofev, Jardiance |
| Corcept Therapeutics | $198.30 | 2023-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.31 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $173.32 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $150.08 | 2022-2024 | Xarelto |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $144.48 | 2021-2024 | |
| Astellas Pharma US INC | $98.49 | 2024-2025 | Veozah |
| Aimmune Therapeutics, INC. | $93.94 | 2024-2025 | Zenpep, Vowst |
| Axsome Therapeutics, INC. | $92.81 | 2023-2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $65.96 | 2021-2022 | |
| Shield Therapeutics INC | $64.70 | 2022-2024 | Accrufer |
| Sumitomo Pharma America, INC. | $62.94 | 2024 | Gemtesa |
| Dexcom, INC. | $57.17 | 2021-2024 | Dexcom G6 Transmitter |
| Corium, LLC | $52.26 | 2023 | Adlarity |
| Seqirus USA INC | $51.57 | 2023-2025 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Ucb, INC. | $45.31 | 2025 | Nayzilam |
| Exact Sciences Corporation | $40.87 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $39.72 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.45 | 2025 | Caplyta |
| Cequr Corporation | $33.58 | 2025 | Cequr Simplicity |
| Lexicon Pharmaceuticals, INC. | $31.37 | 2023-2024 | Inpefa |
| Lundbeck LLC | $31.30 | 2024 | Vyepti |
| Neurocrine Biosciences, INC. | $31.24 | 2024 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $28.75 | 2022 | |
| Sage Therapeutics, LLC | $27.06 | 2024 | |
| Phathom Pharmaceuticals, INC. | $26.17 | 2024-2025 | Voquezna |
| Abbott Laboratories | $24.07 | 2022 | |
| Inari Medical, INC. | $23.35 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Nestle Healthcare Nutrition INC. | $19.31 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.15 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.92 | 2024 | Amvuttra |
| Cmp Pharma, INC. | $18.78 | 2022 | |
| Genentech USA, INC. | $18.09 | 2020 | |
| Ibsa Pharma INC. | $17.81 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.66 | 2023 | Belbuca |
| Biogen, INC. | $17.58 | 2021 | |
| Averitas Pharma INC. | $17.33 | 2024 | Qutenza |
| Sanofi Pasteur INC. | $15.27 | 2023 | |
| Abiomed | $13.36 | 2023 | Impella |
| Grt US Holding, INC. | $8.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fanar Alyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.